On November 10, 2020 BrickBio reported that in site-specific bioconjugation for improved therapeutics via its unnatural amino acid incorporation technology platform, reported that it has expanded on three therapeutic programs and received positive data on its first preclinical novel antibody-drug conjugate, BRKB-28, for breast cancer and gastric cancer (Press release, BrickBio, NOV 10, 2020, View Source [SID1234570981]). The data from a leading CRO that conducted the in vitro testing reported that BRKB-28 did not target nor adversely affect healthy cells, and at the same time eradicated the cancerous targets.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
BrickBio’s platform has the ability to precisely control the DAR (drug to antibody ratio) while producing a homogenous product. The tight control of the DAR contributed to a significantly improved performance profile of BRKB-28 over the leading breast and gastric cancer biologic, which resulted in significant death of healthy cells. Having the broadest and most diverse toolkit of bioconjugation handles, BrickBio is able to site-specifically modify any protein at any site, improving key therapeutic characteristics, such as increased half-life, increased efficacy, decreased dosage and decreased toxicity. Furthermore, the flexible BrickBio platform is payload and linker agnostic, expression host agnostic and produces an entirely homogenous product in every conjugation.
Preclinical Antibody for Breast and Gastric Cancer
The flexibility of the BrickBio platform has enabled the expansion of the company’s therapeutic programs, including "Antibody Drug Conjugates", "Novel Bispecific Antibody Conjugates", and "Novel Scaffolds".
"In addition to ongoing partnerships for technology licensing and co-development of partners’ preferred molecules, we are rapidly building on the breadth of capabilities of the BrickBio platform and expanding our internal pipeline for novel biologics," said Audrey Warner, Head of Business Development at BrickBio and Vice President of Investments at Tiger Gene. "BrickBio will partner on its novel-specific pipeline assets as it continues to expand its therapeutic programs," Warner concluded.
"It is very promising to see the facile integration of our unique bioconjugation platform into any protein scaffold, as validated with our BRKB-28 candidate," said James Italia, VP of Commercial Development at BrickBio. "Our team is able to quickly generate and screen candidates with a variety of scaffolds, linkers, and payloads with exquisite control over their biophysical characteristics. We are already witnessing the benefit of the BrickBio advantage and look forward to future candidates in our other internal programs."
"The robustness and flexibility of the BrickBio platform has enabled the company to progress at a much faster rate than initially forecasted, in terms of developing novel antibody drug conjugates, protein therapeutics, and novel bispecific antibody conjugates," said John Boyce, Co-Founder, Chairman, President and CEO of BrickBio, and Co-Founder of Tiger Gene. "We are not only excited about our first pre-clinical candidate for breast and gastric cancer, but also about the continued work with our pharmaceutical partners to rapidly expand the pipeline across a number of indications," Boyce concluded.